切换导航
关闭
  • 菜单
  • Setting

Chromatin/Epigenetics - Acute Myeloid Leukemia - Lymphoma - Glioma - Multiple Myeloma - Epilepsy

Epigenetics is the heritable modifications in gene expression that is not associated with changes in DNA sequence. Epigenetic modifications occur mostly on DNA or on the histone octamer. There are several types of epigenetics modifications, DNA methylation by DNA-methyl transferase (DNMT) and covalent modification of histones (e.g. acetylation, methylation, phosphorylation and ubiquitination). Histone acetylation by histone acetyltransferases (HATs) is involved in transcriptional activation, whereas histone deacetylation by histone deacetylases (HDACs) is connected with transcriptional repression. Histone demethylation is associated with lysine-specific demethylase (LSD) and JmjC domain containing histone demethylase (JHDM).

The nucleosome is consisted of four histone proteins (H2A, H2B, H3, and H4), they are primary building block of chromatin. The addition and removal of specific chemical groups refers to as epigenetic marks, it regulates chromatin structure and affects gene expression. Moreover, RNA is intimately involved in the formation of a repressive chromatin state.

Epigenetic mechanism responds to environmental changes at the cellular level and thus influences cellular plasticity. Chromatin and epigenetic regulation play a significant role in the programming of the genome during development and stress response, defects in epigenetics can lead to cancer, inflammation and metabolic disorders etc.

20件产品中的 11-20

页面
每页
清除全部
  1. 5-Azacytidine
    A1907 5-Azacytidine
     6 Citation
    中文名: 氮胞苷(5-氮胞苷)
    Target: DNA Methyltransferases
    Summary: DNA甲基转移酶抑制剂
      ≥24.45 mg/mL
      ≥13.55 mg/mL
  2. 3-Deazaneplanocin,DZNep
    A1905 3-Deazaneplanocin,DZNep
     6 Citation
    中文名: 3-去氮腺嘌呤A
    Target: Hydrolase
    Summary: S-腺苷高半胱氨酸和EZH2抑制剂。
      ≥17.07 mg/mL
      ≥17.43 mg/mL
  3. Valproic acid sodium salt (Sodium valproate)
    A4099 Valproic acid sodium salt (Sodium valproate)
    中文名: 丙戊酸钠
    Target: Histone Deacetylases (HDACs)
    Summary: HDAC抑制剂
      ≥8.35 mg/mL
      ≥88.2 mg/mL
  4. Barasertib (AZD1152-HQPA)
    A4112 Barasertib (AZD1152-HQPA)
     3 Citation
    中文名: 巴拉塞替
    Target: Aurora Kinases
    Summary: Aurora Kinase B抑制剂
      ≥25.4 mg/mL
      insoluble in H2O
  5. EPZ005687
    A4171 EPZ005687
     2 Citation
    Target: EZH2
    Summary: EZH2抑制剂
      ≥3.86 mg/mL
      insoluble in H2O
  6. ITF2357 (Givinostat)
    A4093 ITF2357 (Givinostat)
     2 Citation
    Target: Histone Deacetylases (HDACs)
    Summary: HDAC抑制剂
      ≥23.8 mg/mL
      ≥2.9 mg/mL
  7. Rocilinostat (ACY-1215)
    A4083 Rocilinostat (ACY-1215)
     1 Citation
    Target: Histone Deacetylases (HDACs)
    Summary: 选择性的HDAC6抑制剂
      ≥21.675 mg/mL
      insoluble in H2O
  8. Ruxolitinib (INCB018424)
    A3012 Ruxolitinib (INCB018424)
     4 Citation
    中文名: 鲁索替尼
    Target: JAK
    Summary: JAK抑制剂
      ≥15.32 mg/mL
      insoluble in H2O
  9. 3-Deazaneplanocin A (DZNep) hydrochloride
    A8182 3-Deazaneplanocin A (DZNep) hydrochloride
     1 Citation
    中文名: 3-去氮腺嘌呤A盐酸盐
    Target: EZH2
    Summary: SAHH和EZH2抑制剂
      ≥14.94 mg/mL
      ≥18.32 mg/mL
  10. Panobinostat (LBH589)
    A8178 Panobinostat (LBH589)
     10 Citation
    中文名: 帕比司他
    Target: Histone Deacetylases (HDACs)
    Summary: HDAC抑制剂
      ≥17.47 mg/mL
      insoluble in H2O

20件产品中的 11-20

页面
每页